Uncategorized
NIH: Eylea superior to bevacizumab, ranibizumab in visual acuity
Eylea demonstrated superior improvements to mean change in best corrected visual acuity from baseline compared with Avastin and Lucentis injection in a National Institutes of Health-sponsored study, according to a Regeneron press release.The Diabetic Retinopathy Clinical Research Network (DRCR.net) comparative effectiveness study in patients with diabetic macular edema (Protocol T) included 660 patients randomly assigned to treatment with Eylea (aflibercept, Regeneron) 2 mg, Avastin (bevacizumab, Genentech) 1.25 mg, or Lucentis (ranibizumab, Genentech) 0.3 mg.